<DOC>
	<DOCNO>NCT02975336</DOCNO>
	<brief_summary>M2951 investigational drug evaluation treatment autoimmune inflammatory disorder . The purpose study assess Safety Efficacy M2951 Subjects Systemic Lupus Erythematosus ( SLE )</brief_summary>
	<brief_title>A Phase II Study M2951 Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Eligible male female subject , age 18 75 year Must diagnosis SLE either Systemic Lupus International Collaborating Clinics ( SLICC ) criterion SLE , least four 11 American College Rheumatology ( ACR ) classification criterion SLE , least six month duration prior Screening SLEDAI2K total score great equal ( &gt; = ) 6 ( include clinical SLEDAI great equal ( &gt; = ) 4 ) Screening Visit And positive antidoublestranded Deoxyribonucleic Acid ( DNA ) and/or antinuclear antibody ( ANA great equal ( &gt; = ) 1:80 ) time Screening Subjects eligible study active , clinically significant interstitial lung disease pulmonary arterial hypertension Proteinuria ( urine protein creatinine ratio [ UPCR ] &gt; 4 mg/mg ) Acutely worsen renal function Central nervous system SLE Or within two week prior Screening Screening : use oral corticosteroid great equal ( &gt; = ) 30 mg daily prednisone equivalent Use injectable corticosteroid , change dose corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>M2951</keyword>
	<keyword>Placebo</keyword>
	<keyword>Dose response</keyword>
	<keyword>Oral Corticosteroids</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Autoimmune And Inflammatory Disorders</keyword>
</DOC>